Search clinical trials for: Treated with rituximab

Total 160177 results

Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

B-Cell Non-Hodgkin Lymphoma (B-NHL)

Taiwan, Spain, Korea, Republic of, Thailand, Italy, Malaysia, Turkey, Australia
Fondazione Italiana Linfomi - ETS

Recruiting

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (FIL_COLUMN)

Refractory Mantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma

Italy
M.D. Anderson Cancer Center

Recruiting

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy (PACIFIC)

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma

United States
University Hospital, Tours
Hôpital Cochin

Recruiting

Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab (EVAPOR)

Lymphoma, Large B-Cell, Diffuse | Pneumococcal Infections

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide (CLL1818)

Chronic Lymphoid Leukemia | Large-B-cell Diffuse Lymphoma

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Personalized NK Cell Therapy in CBT

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Myelodysplastic Syndrome... and other conditions

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, United States, Spain, Belgium, Austria, Czechia, Australia, Italy, Japan, Hungary, United Kingdom, Taiwan, Turkey, Germany, Canada, France, Israel, Poland, Croatia, Korea, Republic of, Ireland, Russian Federation, Singapore, Sw...
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

B-cell Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Korea, Republic of, Australia, Japan, United Kingdom, Italy, Poland, France, Switzerland, Sweden
SecuraBio

Terminated

Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R)

Follicular Lymphoma

France, Italy, Australia, Poland
Incyte Corporation

Completed

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

B-Cell Malignancies

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (SELENE)

Lymphoma

United States, France, Ukraine, United Kingdom, China, Germany, Spain, Argentina, Belgium, Israel, Russian Federation, Turkey, Japan, Australia, Sweden, Korea, Republic of, Brazil, Puerto Rico, Poland
Abramson Cancer Center at Penn Medicine

Completed

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic | Marginal Zone B-Cell Lymphoma | MALT Lymphoma | Lymphoma of Mucosa-Associated Lymphoid Tissue

United States
University Hospital, Lille
Grifols Biologicals, LLC

Completed

Study of Infections in Patients With Autoimmune Diseases Treated With Rituximab (EXPRIME)

Autoimmune Diseases

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative

United States
Incyte Corporation

Completed

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

B-cell Lymphoma

United States, Spain, Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto
ERIC Group

Completed

Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study (LLC178)

Chronic Lymphocytic Leukemia

Italy
University of California, San Diego
Leadiant Biosciences, Inc.

Terminated

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Acute Lymphocytic Leukemia | Adult Lymphoblastic Lymphoma

United States
Mehrdad Abedi, MD
Amgen

Completed

Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

Stage IV Adult Lymphoblastic Lymphoma | Contiguous Stage II Adult Lymphoblastic Lymphoma | Noncontiguous Stage II Adult Lymphoblastic Lymphoma | Stage I Adult Lymphoblastic Lymphoma | Stage III Adult Lymphoblastic Lymphoma | Untreated Adult Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma

AIDS Related Lymphoma | AIDS-Associated Lymphoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

Lymphoma

United States
SecuraBio

Withdrawn

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
Pfizer

Withdrawn

Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis

Hemophilia A
The Lymphoma Academic Research Organisation

Terminated

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

DLBCL

Belgium, France
National Cancer Institute (NCI)

Completed

Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

AIDS-Related-Primary Central Nervous System Lymphoma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
PETHEMA Foundation
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea; GELCAB

Completed

ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

Lymphoma

Spain
Gilead Sciences

Completed

Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) (Tugela)

Chronic Lymphocytic Leukemia

United States, Hungary, Belgium, United Kingdom, France, Australia, Turkey, Croatia, Italy, Poland, Canada, Greece, Czechia, Ireland, Russian Federation, Spain, Portugal, Romania
Safaa AA Khaled

Unknown

Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy

Viral Hepatitis | ITP - Immune Thrombocytopenic Purpura
University of Miami

Terminated

Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma

Epstein Barr Virus Associated Non Hodgkin's Lymphoma | Epstein Barr Virus Associated Hodgkin's Lymphoma | Post-Transplant Lymphoproliferative Disease

United States
Gilead Sciences

Completed

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, France, United Kingdom, Germany, Italy
Gilead Sciences

Completed

Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland (RETRO-idel)

Chronic Lymphocytic Leukaemia

United Kingdom, Ireland
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Terminated

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Lymphoma | Leukemia | Myeloproliferative Disorders | Myelodysplastic Syndrome | Multiple Myleoma

United States
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (Bridalveil)

Indolent Non-Hodgkin's Lymphomas

United States, Korea, Republic of, Canada, Spain, Taiwan, France, Australia, United Kingdom, Poland, Italy, Israel, Czechia, Germany, Russian Federation, Sweden
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (Yosemite)

Indolent Non-Hodgkin's Lymphomas

United States, Korea, Republic of, Hungary, United Kingdom, Australia, Singapore, Japan, Taiwan, Israel, Italy, Spain, Czechia, Russian Federation, France, Poland, Romania, Germany, Portugal, Sweden
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

Lymphoma | Leukemia

United States
Weill Medical College of Cornell University
Celgene Corporation

Terminated

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia (THRiL for WM)

Waldenstrom Macroglobulinemia

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Simon Krabbe
Zealand University Hospital; University of Aarhus; University of Southern Denmark

Completed

Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs

Rheumatoid Arthritis | Psoriatic Arthritis | Spondyloarthritis
Millennium Pharmaceuticals, Inc.

Completed

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Transformed Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Burkitt's Lymphoma

United States, Spain, Italy, United Kingdom
Sandoz
Hexal AG

Completed

GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera® (ASSIST-RT)

Rheumatoid Arthritis

United States, Germany, Poland, Hungary
Samsung Medical Center

Completed

Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab

Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma | Patients Treated With Rituximab-CHOP or Rituximab-CVP

Korea, Republic of, Malaysia, Singapore, China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Western Regional Medical Center

Withdrawn

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Lymphoma | Hodgkin's Lymphoma | Non-hodgkin's Lymphoma

United States
University of Miami

Terminated

Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP) (R-CHOP)

Lymphoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Study of Biomarkers Using Tissue Samples From Older Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab on Clinical Trial ECOG-E4494

Lymphoma
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab

Lymphoma

Search clinical trials for: Treated with rituximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations